leadf
logo-loader
viewSUDA Pharmaceuticals Ltd

SUDA Ltd to reveal agreement

The halt will remain in place until Thursday 6th July 2017.

shutterstock_578045545_595adbf88c7d4.jpg
SUDA is focused on drug delivery

SUDA Ltd (ASX:SUD) has some material news pending in the form of a licence agreement.

The ASX has granted the company a trading halt to prepare details, with its shares placed in pre-open.

The halt will remain in place until the opening of trade on Thursday 6th July 2017, or earlier if an announcement is made to the market.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.042 AUD

ASX:SUD
Market: ASX
Market Cap: $16.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead...

Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive's Andrew Scott soon after announcing they've received Therapeutics Goods Administration (TGA) approval for their lead product ZolpiMist for the treatment of short-term insomnia in adults. Baker says it's a...

on 31/7/20

2 min read